Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122827
Filing Date
2024-11-07
Accepted
2024-11-07 08:10:22
Documents
69
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q hlvx-20240930.htm   iXBRL 10-Q 1690486
2 EX-31.1 hlvx-ex31_1.htm EX-31.1 16835
3 EX-31.2 hlvx-ex31_2.htm EX-31.2 16778
4 EX-32.1 hlvx-ex32_1.htm EX-32.1 9425
5 EX-32.2 hlvx-ex32_2.htm EX-32.2 9273
  Complete submission text file 0000950170-24-122827.txt   8120332

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT hlvx-20240930.xsd EX-101.SCH 1420866
71 EXTRACTED XBRL INSTANCE DOCUMENT hlvx-20240930_htm.xml XML 1319037
Mailing Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118
Business Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118 (617) 213-5054
HilleVax, Inc. (Filer) CIK: 0001888012 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41365 | Film No.: 241433310
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)